Mylan Completes Acquisition of Generics Business of Merck KGaA

Mylan Completes Acquisition of Generics Business of Merck KGaA

October 03, 2007

PITTSBURGH, Oct. 3 /Xinhua-PRNewswire/ -- 

    Mylan (NYSE: MYL) announced today that it has completed
its acquisition of Merck KGaA's generics business
("Merck Generics") to become one of the largest
quality generics and specialty pharmaceuticals companies in
the world.  Mylan and Merck KGaA initially announced the
signing of a definitive agreement under which Mylan would
acquire Merck Generics for EUR 4.9 billion ($6.8 billion)
in an all-cash transaction on May 12, 2007. 

    Robert J. Coury, Mylan's Vice Chairman and Chief
Executive Officer said, "The new Mylan now has all of
the critical attributes we need to ensure future success
and deliver powerful growth.  We have enhanced scale and
stability, a truly global reach, vertical and horizontal
integration, and breadth and depth in our management team. 
Most importantly, we have a common purpose and dedication to
executing on our strategy and delivering superior
shareholder returns."

    The new Mylan is the third largest generic company
worldwide, employs more than 11,000 people and has a global
presence in more than 90 countries.  Mylan's broad product
offering now includes more than 570 products and the
world's second largest portfolio of active pharmaceutical
ingredients (APIs) with 126 U.S. drug master files (DMFs). 
Mylan has a powerful global pipeline with more than 255
applications or dossiers pending regulatory approval.   The
new Mylan will benefit from substantial operational
efficiencies and economies of scale from increased sales
volumes and its vertically and horizontally integrated
platform.  Dey, Mylan's specialty pharmaceuticals business,
brings additional exciting and diversified opportunities
through its existing strengths in the respiratory arena.

    Mr. Coury continued, "The scale of the new Mylan
is evident in every area of our business: we have scale in
our geographic reach, scale in R&D, scale in
manufacturing, scale in API, scale in our combined product
portfolio, and scale in our global commercial footprint. 
We will leverage this scale to drive operational
efficiencies and extract synergies from our combined
company, while attracting exciting new opportunities.  We
have also created an extremely well-balanced and
diversified company, with significantly reduced risks
related to any one particular market or product. 
Importantly, we will also ensure that we retain the
qualities that customers around the world have come to
expect from both Mylan and Merck Generics. 

    "The Merck Generics business is even stronger than
we expected and, through the integration planning, we have
confirmed that we truly share a common culture and values
centered on quality, integrity, reliability and service.  I
am thrilled to welcome Merck Generics nearly 5,000 employees
to the new and expanded Mylan family.  After months of
careful preparation, we have hit the ground running with
the integration of our businesses and I am delighted that
we will be operating as a single, integrated company from
day one."

    Mylan also announced today that the company will change
its name from Mylan Laboratories Inc. to Mylan Inc. to
better reflect the broader scope of its business.  The
Company also confirmed that it has changed its financial
year to begin reporting on a calendar year basis.

    Investor Day on October 3

    Mylan will provide more details on its go-forward
strategy and its financial outlook during its Investor Day
in New York, New York, on October 3, 2007.  The agenda will
include presentations delivered by each of Mylan's global
regional heads and several members of Mylan's senior
management team.  The presentations will be available live
via webcast beginning at 8:30 a.m. ET. 

    To access the live webcast, go to Mylan's Web site at
www.mylan.com and click on the webcast icon at least 15
minutes before the event is scheduled to begin to register
and download or install any necessary audio software. A
replay of the webcast will be available on
http://www.mylan.com until November 2, 2007.

    About Mylan

    Mylan Inc. is one of the world's leading quality
generic and specialty pharmaceutical companies. The Company
offers one of the industry's broadest and highest quality
product portfolios, a robust product pipeline and a global
commercial footprint through operations in more than 90
countries.  Through its controlling interest in Matrix
Laboratories Limited, Mylan has direct access to one of the
largest active pharmaceutical ingredient (API) manufacturers
in the world.  Dey L.P., Mylan's fully integrated specialty
business, provides the Company with innovative and
diversified opportunities in the respiratory and allergy
therapeutic areas.  

    For more information about Mylan, please visit
http://www.mylan.com .
 
    Forward-Looking Statements

    This press release contains statements that constitute
"forward-looking statements", including with
regard to Mylan's future success, the anticipated benefits
of operational efficiencies and leverage, and expected
product and other opportunities.  These statements are made
pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995.  Because such
statements inherently involve risks and uncertainties,
actual future results may differ materially from those
expressed or implied by such forward-looking statements. 
Factors that could cause or contribute to such differences
include, but are not limited to: challenges and costs
relating to integration of the two businesses; the effect
of any changes in customer and supplier relationships and
customer purchasing patterns; the impact and effects of
legal or regulatory proceedings, actions or changes;
general market perception of the transaction; the ability
to attract and retain key personnel; changes in economic
and financial conditions of the Company's business;
uncertainties and matters beyond the control of management;
and the other risks detailed in the Form 10-Q for the
quarter ended June 30, 2007 and the other periodic reports
filed by the Company with the Securities and Exchange
Commission.  The Company undertakes no obligation to update
these statements for revisions or changes after the date of
this release. 


    For more information, please contact:

     Kris King, 
     Mylan Inc.
     Tel:   [phone]

     Nina Devlin or Cindy Leggett-Flynn,
     Brunswick Group
     Tel:  [phone]